UNDERSTANDING HEPATITIS C: A COMPREHENSIVE OVERVIEW
Hepatitis C is a global health challenge, affecting millions. Pharmacists play a crucial role in managing this disease, understanding its treatment and supporting patients.
Virology and Transmission Hepatitis C is caused by the Hepatitis C virus (HCV), a single-stranded RNA virus belonging to the Flaviviridae family. With six major genotypes the virus's genetic diversity influences disease progression and treatment response, making genotype determination vital. HCV is primarily transmitted through blood-to-blood contact, including injection drug use, healthcare exposure, vertical transmission from mother to child, and, less commonly, sexual contact.
Clinical Presentation and Complications HCV infection ranges from asymptomatic cases to severe liver disease. It has two stages:
Acute Hepatitis C: Occurs within the first six months of exposure. Many are asymptomatic or experience mild symptoms like fatigue, jaundice, nausea, and abdominal pain. About 15-25% of cases clear spontaneously.
Chronic Hepatitis C: If the virus persists beyond six months, it is considered chronic. This stage can remain asymptomatic for years while causing liver damage, leading to cirrhosis, liver failure, and hepatocellular carcinoma. Chronic HCV is a leading cause of liver transplants.
Regular screening and early detection are essential due to the often-silent progression of the disease.
Diagnosis Diagnosing HCV involves several steps: • Screening Tests: Initial tests like enzyme immunoassay (EIA) or chemiluminescent immunoassay (CIA) detect HCV antibodies.
• Confirmatory Tests: A positive antibody test requires a nucleic acid test (NAT) for HCV RNA to confirm active infection.
• Genotype Testing: Guides treatment decisions. • Liver Assessment: Liver function tests (LFTs) and imaging studies assess liver damage, sometimes necessitating a liver biopsy.
Pharmacists should understand these steps to guide patients through their treatment journey.
Treatment The treatment landscape for HCV has transformed with the advent of direct-acting antivirals (DAAs), offering high cure rates and fewer side effects compared to previous treatments. Key considerations in treatment include: • Genotype: Influences the choice of DAA regimen.
• Previous Treatment History: Treatment- naive versus treatment-experienced patients may need different approaches.
• Cirrhosis Status: Affects treatment choice and duration.
• Drug-Drug Interactions: Pharmacists must identify potential interactions with other medications and supplements.
Typical treatment durations range from 8 to 12 weeks, aiming for a sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks post-treatment, indicating a cure.
Pharmacists are integral to the HCV management involved in: • Patient Education: Teaching about transmission prevention, treatment adherence, and DAA side effects.
• Medication Management: Ensuring correct DAA administration and managing drug interactions.
• Support and Counselling: Supporting lifestyle changes like reducing alcohol intake and maintaining a healthy diet.
• Advocacy and Screening: Promoting routine screening in high-risk populations and advocating for better access to treatment.
scottishpharmacist.com 41
REGULAR SCREENING AND EARLY DETECTION ARE ESSENTIAL DUE TO THE OFTEN-SILENT PROGRESSION OF THE DISEASE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
